Trials / Terminated
TerminatedNCT01641926
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 402 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen \[HBeAg\] positive or negative) who have not previously been treated with interferon.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PEG-Intron™ | PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks |
| BIOLOGICAL | PEGASYS™ | PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks |
Timeline
- Start date
- 2012-11-26
- Primary completion
- 2016-01-21
- Completion
- 2016-01-21
- First posted
- 2012-07-17
- Last updated
- 2018-08-27
- Results posted
- 2017-01-12
Source: ClinicalTrials.gov record NCT01641926. Inclusion in this directory is not an endorsement.